Daratumumab: Therapeutic asset, biological trap!
Author:
Publisher
Elsevier BV
Subject
Biochemistry, medical,Clinical Biochemistry,Hematology
Reference37 articles.
1. Multiple myeloma;Kyle;N Engl J Med,2004
2. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma;Nijhof;Blood,2016
3. Novel agents in the treatment of multiple myeloma: a review about the future;Naymagon;J Hematol Oncol,2016
4. Risk of progression and survival in multiple myeloma relapsing after therapy with IMIDs and bortezomib: a multicenter international myeloma working study group;Kumar;Leukemia,2012
5. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing;De Vooght;Curr Opin Hematol,2016
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?;Vox Sanguinis;2024-05-05
2. Daratumumab-Induced Interference in Flow-Cytometry Crossmatch and Resolving It by DTT Treatment;The Korean Journal of Blood Transfusion;2023-12-31
3. Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping;Transfusion;2022-10-14
4. Pseudo-Kappa Light Chain Restricted Hematogones in Patients Receiving Daratumumab;Turkish Journal of Hematology;2021-11-18
5. RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?;Transfusion;2021-11-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3